ProfileGDS5678 / 1438477_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 71% 77% 76% 76% 69% 62% 68% 76% 73% 70% 74% 70% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5730272
GSM967853U87-EV human glioblastoma xenograft - Control 24.5002871
GSM967854U87-EV human glioblastoma xenograft - Control 35.2658877
GSM967855U87-EV human glioblastoma xenograft - Control 45.294976
GSM967856U87-EV human glioblastoma xenograft - Control 55.068776
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.274669
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8035662
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1737968
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0467976
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.78473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.379470
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9305474
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3709470
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9259375